Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $61
Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept's Potential in IgA Nephropathy
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
Analysts Are Bullish on Top Healthcare Stocks: Vera Therapeutics (VERA), Erasca (ERAS)
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load?
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71
Vera Therapeutics Analyst Ratings
J.P. Morgan Maintains Vera Therapeutics(VERA.US) With Buy Rating, Announces Target Price $71
Vera Therapeutics | 10-K: FY2024 Annual Report
TD Cowen Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $60
Guggenheim Maintains Vera Therapeutics(VERA.US) With Buy Rating, Cuts Target Price to $61
Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Express News | Vera Therapeutics Inc : Guggenheim Raises Target Price to $61 From $59
Wells Fargo Maintains Vera Therapeutics(VERA.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)
Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook
Vera Therapeutics 2024 Loss Widens
Press Release: Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results